This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Karyopharm Therapeutics Inc. [KPTI], a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, will visit the NASDAQ MarketSite in Times Square.
Karyopharm completed a successful IPO in November 2013, which raised gross proceeds of over $125M.
Karyopharm presented data from the Phase 1 trial of its lead drug candidate, Selinexor (KPT-330), in patients with heavily pretreated hematologic malignancies at the 2013 American Society of Hematology Annual Meeting showing preliminary evidence of broad anti-cancer activity as an oral, single agent therapy.
Data were also presented at the American Society of Clinical Oncology 2014 Gastrointestinal Cancers Symposium from the Phase 1 study of Selinexor showing preliminary evidence of antitumor activity in metastatic colorectal cancer patients whose tumors were progressing at the start of the study.
Karyopharm expects to initiate registration-directed trials of Selinexor in the first half of 2014.
Sharon Shacham, Ph.D., M.B.A., Founder, President and Chief Scientific Officer and Michael Kauffman, M.D., Ph.D., Chief Executive Officer, will ring the Closing Bell. Drs. Shacham and Kauffman will be joined by the entire Karyopharm team to celebrate the occasion.
NASDAQ MarketSite – 4 Times Square – 43
rd & Broadway – Broadcast Studio
Thursday, February 6, 2014 – 3:45 p.m. to 4:00 p.m. ET
Contact: Beth DelGiacco (212) 362-1200
firstname.lastname@example.orgNASDAQ MarketSite: Christine Barna (646) 441-5310
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC 3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at:
For photos from ceremonies and events visit our Instagram Page:
For news tweets, please visit our Twitter page at:
For exciting viral content and ceremony photos visit Tumblr Page:
A LiveStream of the NASDAQ Closing Bell will be available at:
To obtain a hi-resolution photograph of the Market Close, please go to
http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.
About Karyopharm Therapeutics Inc. [KPTI]:
Karyopharm Therapeutics Inc. (Nasdaq:KPTI) is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. Karyopharm's SINE compounds function by blocking XPO1, preventing the export of various proteins out of the nucleus. SINE compounds have shown biological activity in models of cancer, autoimmune disease, certain viruses, and wound-healing. Karyopharm was founded by Dr. Sharon Shacham and is located in Natick, Massachusetts.